anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Anshen Dingzhi prescription (ADP), documented in "Yi Xue Xin Wu", is a famous prescription for treating panic-related mental disorders such as post-traumatic stress disorder (PTSD). However, the underlying mechanism remains unclear.
AIM OF THE STUDY: This study aimed to investigate the mechanisms by which ADP intervened in PTSD-like behaviors.
METHODS: A mouse model of single prolonged stress (SPS) was established to evaluate the ameliorative effects and mechanisms of ADP on PTSD. Behavioral tests were used to assess PTSD-like behaviors in mice; transmission electron microscopy was used to observe changes in the ultrastructure of hippocampal synapses, and western blot, immunofluorescence, and ELISA were used to detect the expression of hippocampal deleted in colorectal cancer (DCC) and downstream Ras-related C3 botulinum toxin substrate 1 (Rac1) - P21-activated kinase 1 (PAK1) signal, as well as levels of synaptic proteins and inflammatory factors. Molecular docking technology simulated the binding of potential brain-penetrating components of ADP to DCC.
RESULTS: SPS induced PTSD-like behaviors in mice and increased expression of hippocampal netrin-1 (NT-1) and DCC on the 14th day post-modeling, with concurrent elevation in serum NT-1 levels. Simultaneously, SPS also decreased p-Rac1 level and increased p-PAK1 level, the down-stream molecules of DCC. Lentiviral overexpression of DCC induced or exacerbated PTSD-like behaviors in control and SPS mice, respectively, whereas neutralization antibody against NT-1 reduced DCC activation and ameliorated PTSD-like behaviors in SPS mice. Interestingly, downstream Rac1-PAK1 signal was altered according to DCC expression. Moreover, DCC overexpression down-regulated N-methyl-d-aspartate (NMDA) receptor 2A (GluN2A) and postsynaptic density 95 (PSD95), up-regulated NMDA receptor 2B (GluN2B) and increased neuroinflammatory responses. Administration of ADP (36.8 mg/kg) improved PTSD-like behaviors in the SPS mice, suppressed hippocampal DCC, and downstream Rac1-PAK1 signal, upregulated GluN2A and PSD95, downregulated GluN2B, and reduced levels of inflammatory factors NOD-like receptor protein 3 (NLRP3), nuclear factor kappa-B (NF-κB) and interleukin-6 (IL-6). Importantly, DCC overexpression could also reduce the ameliorative effect of ADP on PTSD. Additionally, DCC demonstrated a favorable molecular docking pattern with the potential brain-penetrating components of ADP, further suggesting DCC as a potential target of ADP.
CONCLUSION: Our data indicate that DCC is a key target for the regulation of synaptic function and inflammatory response in the onset of PTSD, and ADP likely reduces DCC to prevent PTSD via modulating downstream Rac1-PAK1 pathway. This study provides a novel mechanism for the onset of PTSD and warrants the clinical application of ADP.
Participants will be treated with intravenous infusions of MC0518 at a dose of 1 to 2\*10\^6 cells per kilogram (cells/kg) (based on body weight at the Screening Visit). Infusions will be administered once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
The invention relates to a preparation method of a traditional Chinese medicine composition for treating postpartum anemia and lochia. The traditional Chinese medicine composition comprises medicinal components as follows: melanterite, sea-buckthorn, hawthorn and Chinese-date. As an assistant and guide principle, the medicinal components appropriately cooperate with each other and can treat the symptoms and roots, and therefore, the traditional Chinese medicine composition is particularly suitable for rapidly improving anemia symptoms and treating postpartum blood-insufficiency anemia and prolonged lochia and can be used for anemia treatment of chronic nephrosis patients. Oral liquid prepared from the traditional Chinese medicine composition has good taste and is free of stimulation to the gastrointestinal tract. In the preparation method, sodium hydroxide is firstly added into mixed medicinal liquid, and because sodium hydroxide is stable alkali, in a production process, surplus sulfuric acid is naturalized by sodium hydroxide so that the pH value of the whole medicinal liquid is stable; then, corresponding chelation is carried out by using citric acid to form chelating Fe; the symptoms such as black spot teeth and black excrement in an oral administration process are avoided. The oral liquid tastes sour and sweet and is in good compliance property of patients; a clinical research proves that hemoglobin is quickly increased, and the traditional Chinese medicine composition is long in action time and can be used for tonifying qi and blood. Therefore, the traditional Chinese medicine composition is the best medicine for treating postpartum anemia and can also obviously improve the sleep quality of the patients.
Carcinogenicity studies with dabrafenib have not been conducted. TAFINLAR increased the risk of cuSCCs in patients in clinical trials.

Dabrafenib was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test) or the mouse lymphoma assay and was not clastogenic in an in vivo rat bone marrow micronucleus test.

In a combined female fertility and embryo-fetal development study in rats, a reduction in fertility was noted at doses greater than or equal to 20 mg/kg/day (equivalent to the human exposure at the recommended adult dose based on AUC). A reduction in the number of ovarian corpora lutea was noted in pregnant females at 300 mg/kg/day (which is approximately three times the human exposure at the recommended adult dose based on AUC).

Male fertility studies with dabrafenib have not been conducted; however, in repeat-dose studies, testicular degeneration/depletion was seen in rats and dogs at doses equivalent to and three times the human exposure at the recommended adult dose based on AUC, respectively.
A pilot, random research with 10 participants was undertaken. Two groups, Experimental group and Control group, were randomly selected among the subjects. Participant completed the informed consent form before the navicular drop test and Harris Mat was used to measure the foot pressure. Footcore exercises and conventional therapy was given for four weeks ,twice a day for 6 days. While the Control group just received conventional treatment, the Experimental group combined Footcore exercise with it. The data will be analyzed using SPSS 26.0 software.
The present invention relates to a method for treating a cancer having a protein kinase gene fused to a gene coding for a nuclear-envelop protein or a protein interacting with the nuclear envelop in a subject comprising administering to the subject a therapeutically effective of an arsenic compound, an inductor of type 1 IFNs and a tyrosine kinase inhibitor (TKI), as combined preparation. Indeed, inventors have validated the present invention with in vivo and in vitro models. Treatments started in mice with leukemic burden being >3% (up to 90%) hCD45+CD7+ cells in the blood as detected by flow cytometry in individual tested mice. DASA (20mg/Kg, diluted in 80mM citric acid, pH2.1) was delivered using per os administration. ATO (5mg/Kg, diluted in TBS, pH7) and PolyI:PolyC (PIPC, 20mg/Kg diluted in PBS, SIGMA) were injected using intraperitoneal route. The time scale of drug delivery is indicated for every experiment performed. Mice were weighed every day of treatments, in order to ensure they were not losing too much weight and also to adjust the delivered drug doses. DASA+ATO+PIPC treated mice had a significantly prolonged survival compared to the other treatment conditions, showing major differences between results of treatment protocols. ATO combined with IFN-type 1 inducers and inhibitors of TK represents a powerful way for eradication of T-ALL cells that implicate high ABL1 activity and nuclear pore protein lesions.
OBJECTIVES: Sturge Weber syndrome (SWS) is a neurovascular condition with an estimated incidence of 1 in 20,000 to 50,000 live births. SWS Types I and II involve cutaneous and ophthalmological findings, with neurological involvement in Type I. SWS Type III is exclusive to brain stigmata. Our study aims to describe the characteristics of brain MRI findings and report neuroradiological features with seizure and cognitive outcomes in patients with SWS Type III.
METHODS: This is a retrospective case series examining the clinical, radiological, and cognitive characteristics of patients with SWS Type III referred to the SWS Clinic at Boston Children's Hospital. We analyzed brain MRI findings based on vascular and parenchymal features. Clinical and cognitive outcomes were based on a validated assessment tool in this population (Neuroscore).
RESULTS: This dedicated case series of patients with Type III SWS from a single center identified ten patients. All patients had classic stigmata indicative of SWS. Two distinct radiological phenotypes were found, one characterized by more pronounced deep venous enlargement, and the other, with more pronounced parenchymal abnormalities. There was heterogeneity in seizure presentation and outcome. Earlier age of onset and seizures predict more severe outcomes, as seen in classic SWS.
CONCLUSION: We could not find significant divergence in outcomes between patients with differing neuroimaging phenotypes. These results raise the question of whether the two distinct radiological phenotypes found in SWS Type III are reflective of different disease entities, with underlying genetic heterogeneity. These results suggest the need for larger, multi-center natural history studies.
Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
It is widely accepted and scientifically confirmed that physical activity improves child health with positive effects on adiposity, musculoskeletal health and fitness, and cardiovascular health. Beyond the health benefits of physical activity alone, participation in sports at this crucial age enhances psychological and social health outcomes. Athletes with Sever's symptoms are limited in their ability to participate in physical activity and athletics, and it is suggested that active intervention in the management of Sever's is most appropriate to improve quality of life and outcomes without substantial time lost from sport or physical activity. Therefore, efficient and effective treatment is essential, especially for active and competitive athletes.

Standard treatment for Sever's disease is placement of heel cups in shoes and stretching or physical therapy. These interventions are effective in reducing Sever's patients' heel pain. A retrospective study showed that with treatment with a heel cup or other foot orthoses, symptoms improved within 2 months. However, there remains a distinct lack of randomized control trials evaluating treatments for Sever's in the literature. For the many young athletes with Sever's who participate in barefoot sports such as gymnastics, dance, or tae kwan do, the standard treatment is inadequate. They cannot use the recommended heel cups, which are placed in an athletic shoe. Currently, two braces are commonly used for barefoot athletes with Sever's: Cheetah Heel Cups and The X Brace. Neither of these braces are currently FDA approved as they are not considered medical devices and are marketed as an insert. Health care providers often recommend barefoot athletes purchase these braces, but no published studies evaluating their effectiveness exist in the established literature. This study will compare these two braces in an investigator-blinded, randomized control trial in order to contribute to the understanding of standard treatment for barefoot athletes with Sever's disease and improve patient outcomes by affecting clinical practice. In light of the paucity of information on and the importance of optimizing patient outcomes to improve quality of life and maintain an active lifestyle for young barefoot athletes, this prospective, randomized treatment study will compare the effectiveness of two braces in decreasing pain severity in barefoot athletes diagnosed with Sever's disease.
The invention provides a mammalian mucinase capable of hydrolyzing mucin. The mucinase is among others suitable for counteracting diseases in which mucus is involved. The diseases comprise cystic fibrosis, COPD, asthma, bronchitis, tuberculosis, tumors with altered mucus expression, and mucus-containing pathogens. The invention also provides a pharmaceutical composition comprising an effective amount of the mucinase and a method of therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved. Methods for obtaining the mucinase are also herewith provided, as well as nucleic acids encoding (part of) the mucinase. In one aspect, the invention provides a diagnostic kit comprising a mucinase, a mucinase-specific antibody, a mucinase-derived peptide and/or nucleic acid encoding (part of) the mucinase.
A biopsy forceps (1) comprises a flexible pipe (2) which can be remotely controlled. Two handles (6 and 7) which are connected to the near end of the pipe are used for operating a pair of clamps (4 and 5) that are connected to the far end of the pipe. An independent control handle (8) comprises a rotatable knob (16). The knob rotates in the reverse direction to facilitate the bending of the pipe in the second direction. A control knob can be connected to the far end of the pipe through the operating lines (42 and 43) that moves in the cavities (44 and 45) of the pipe in company with the rotation of the knob. The clamps (or other control component) at the far end of the pipe are replaceable (80A and 80B).
Stroke is a debilitating condition that can impair multiple functions, including swallowing. Stroke patients with dysphagia, are known to have reduced cough due to multiple mechanisms and this can impair their expectorate function. This can lead to accumulation of sputum and mucoid, ultimately resulting in aspiration pneumonia. Stroke patients, especially those with dysphagia, are also known to have expiratory muscle weakness and weak cough than healthy controls. Stroke patients are also known to have reduced diaphragm movement than healthy subjects. Sonography is a useful tool that can easily and reliability measure diaphragm movement. Whether stroke patients with dysphagia have reduced diaphragm movement than those without dysphagia and whether this affects voluntary cough have not been reported yet.

This study attempts to evaluate diaphragm movements during voluntary cough in stroke patients with dysphagia and determine whether this reduced diaphragm movement correlates to their peak flow meters during voluntary cough.
An incision of 15\~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth I, Billroth II or Roux en Y method was used for gastric reconstruction.
<P>PROBLEM TO BE SOLVED: To provide a water-erodible pharmaceutical delivery device exhibiting good adhesion and localized drug delivery capability without giving patients minimal discomfort, a necessity in this field.  <P>SOLUTION: The pharmaceutical delivery device includes a layered film having a first water-erodible adhesive layer arranged to contact the mucosal surface and a second water-erodible non-adhesive backing layer containing hydroxypropyl cellulose and an alkyl cellulose. The device may have drugs included in the first layer, the second layer and both. The alkyl cellulose is ethyl cellulose. The ratio of hydroxypropyl cellulose to ethyl cellulose is 1,000:1-3:1.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Patients receive anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of following EGFR-TKIs: Gefitinib is administered 250 mg once per day. Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
Compositions containing nicotinamide riboside (NR) are provided. NR containing compositions are used in the care or treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing nicotinamide riboside. In further embodiments, the invention relates to methods of using nicotinamide riboside to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival. A method of treating signs or symptoms of aging or skin wrinkles in an individual is provided, comprising topically administering to the individual in need of such treatment an effective amount of the compound nicotinamide riboside, or salts thereof. In a particular embodiments of the invention, it is a topical composition comprising nicotinamide riboside for treating skin conditions relating to UV (ultra-violet) mediated DNA damage, oxidative stress or wound healing.
Less frequently reported adverse reactions are vaginal bleeding, vaginal discharge, menstrual irregularities, skin rash and headaches. Usually these have not been of sufficient severity to require dosage reduction or discontinuation of treatment. Very rare reports of erythema multiforme, Stevens-Johnson syndrome, bullous pemphigoid, interstitial pneumonitis, and rare reports of hypersensitivity reactions including angioedema have been reported with tamoxifen citrate therapy. In some of these cases, the time to onset was more than one year. Rarely, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen citrate (see PRECAUTIONS- Drug/Laboratory Testing Interactions section).   
  
To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
ABSTRACT OF THE DISCLOSURE      The invention relates primarily to pharmaceutical compositions and medicaments containing a compound of Formula (I), infra as the active ingredient.  Also included in the invention are methods for combatting ? ? illnesses by administracion of an active compound of the invention alone, in combination with ? ? or in the form of amedicament.
The present invention relates to system and method for collecting medical information of an applicant in a home country for an employment determination as foreign worker in a predetermined destination country via a computer-implemented system. More particularly, the present invention relates to a system, method and software program product for a process which is an integration of a plurality of modules which are controlled and managed by a single provider entity. One of the advantages of the system for collecting medical information of an applicant in a home country for an employment determination as foreign worker in a predetermined destination country of the present invention is that it reduces time and labor for employment determination in destination country. In addition, the system prevents any falsification or fraudulent of the medical reports in home country. In addition, the risks of foreign workers spreading contagious diseases in a destination country is prevented and eliminated. The system of the present invention can be used to secure any information, area, device, machine, or transaction and it is possible to confirm the identity of the applicant. Another advantage of the present invention is that the database of the system is searchable to retrieve information related to a specific employee, a specific country, a specific healthcare screening medical reports, a specific technical skill or any other searchable criteria.
This study involves a controlled trial of an optimized version of a weight management and physical activity psycho-educational intervention (called MOVE!) for overweight and obese Veterans with serious mental illness. The study hypothesizes that MOVE! will result in weight loss and improved indicators of cardiovascular risk when compared to usual care. Medical outcomes are proportion achieving 4% or higher weight loss, mean weight loss, and reductions in cardiovascular risk (blood pressure, glucose and serum lipids). Psychosocial outcomes are general health, psychiatric functioning, quality of life, and self-esteem and medication adherence. Mediators include physical activity, dietary management, self-efficacy, and motivation/readiness to change. The intervention involves a well specified combination of individualized and group based services and draws on evidence based techniques and materials that are currently well packaged in an existing VA program called MOVE! The Comparison condition is operationalized as usual treatment plus monthly weight measurements and distribution of educational brochures regarding diet and exercise.
<P>PROBLEM TO BE SOLVED: To provide a granulated substance of barley young leaf powder having breath odor eliminating effect.  <P>SOLUTION: The breath odor eliminating food comprising a granulated substance of barley young leaf powder is obtained by adding water or both of water and ethanol to barley young leaf powder, kneading the mixture, subjecting the kneaded mixture to extrusion molding, and drying the molded mixture. The food is edible as it is, and excellent in palate feeling such as chewiness. The food has odor eliminating effect (breath odor eliminating effect) because the green-colored barley young leaf powder contains rich dietary fibers and chlorophyll. Addition of an odor eliminating component such as chlorophyll to the barley young leaf powder before granulation enhances the breath odor eliminating effect.  <P>COPYRIGHT: (C)2003,JPO
Every patient included in the CTA+CDU group preoperatively underwent CT angiography of the abdominal wall. Based on the CTA examination XY coordinates of DIEA perforators localized within the area between 2 cm cranial and 10 cm caudal from the umbilicus and with a vessel calibre of more than 1 mm were determined. The day before the surgery, the main perforators were marked on the patient's abdomen according to the coordinates deducted from the CTA. These perforators were additionally examined using a LOGIQ S8/V1 CDU device with a linear transducer of frequency 4-11 MHz. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
PURPOSE:To obtain the subject agent excellent in compatibility with a silicone, having a solubilization property, having a low skin irritation and excellent in safety and stability by blending one or more compounds selected from specified branched monoesters such as isooctyl isonananate. CONSTITUTION:An agent for dissolution or solubilization of silicones containing one or more compounds selected from branched monoesters (e.g. isononyl isomyristate) represented by the formula (R1 is alkyl residue of 5-18C isocarboxylic acid; R2 is alkyl residue of 3-18C isoalcohol). As the above- mentioned esters are excellent in solubility and solubilization properties, the esters can reduce limitation about the amount of silicones used in a silicone- containing product and can extend the usage thereof. In the respect of functions, a system is stabilized by dissolution or solubilization of a silicone and excellent functions of the silicone is fully shown therefor. In addition, the above mentioned agent is excellent in irritability, safety and stability also.